Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Catheter Precision Inc. (VTAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: VTAK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -93.79% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.76M USD | Price to earnings Ratio 0.02 | 1Y Target Price 41 |
Price to earnings Ratio 0.02 | 1Y Target Price 41 | ||
Volume (30-day avg) 152943 | Beta - | 52 Weeks Range 0.30 - 8.40 | Updated Date 02/26/2025 |
52 Weeks Range 0.30 - 8.40 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 30.61 |
Earnings Date
Report Date 2025-03-27 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2921.51% |
Management Effectiveness
Return on Assets (TTM) -21.56% | Return on Equity (TTM) -49.81% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value 3645753 | Price to Sales(TTM) 7.59 |
Enterprise Value 3645753 | Price to Sales(TTM) 7.59 | ||
Enterprise Value to Revenue 9.14 | Enterprise Value to EBITDA 0.08 | Shares Outstanding 8004630 | Shares Floating 962431 |
Shares Outstanding 8004630 | Shares Floating 962431 | ||
Percent Insiders 13.53 | Percent Institutions 4.66 |
Analyst Ratings
Rating 5 | Target Price 41 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Catheter Precision Inc.
Company Overview
History and Background
Catheter Precision Inc., now known as Adagio Medical, Inc., was founded with a focus on developing and marketing innovative technologies for electrophysiology procedures. The company has focused on improving catheter-based treatments for cardiac arrhythmias.
Core Business Areas
- Mapping and Navigation: Adagio Medical provides advanced mapping and navigation systems that enable electrophysiologists to precisely locate and ablate cardiac arrhythmias.
- Ablation Technologies: Adagio Medical develops and offers ablation catheters for treating various types of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia.
Leadership and Structure
Information on specific individuals holding leadership positions is available via public filings. The organizational structure is typical for a medical device company, with departments focused on research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- CEASE-AFib: Formerly known as the Amigo Remote Steering System and VIVO 3D Mapping System. It allows precise localization of pulmonary vein anatomy in real-time without fluoroscopy, with integration of electrophysiological data, and offers remote catheter steering for targeted positioning and ablation. Competitors include Biosense Webster (JNJ), Abbott, and Boston Scientific.
- Ablation Catheters: Catheter Precision manufactures specific ablation catheters used in conjunction with its mapping system. Detailed market share data is not publicly available. Competitors: Biosense Webster (JNJ), Abbott, Boston Scientific.
Market Dynamics
Industry Overview
The electrophysiology market is growing due to the increasing prevalence of cardiac arrhythmias like atrial fibrillation. Advancements in ablation technologies and mapping systems are driving market expansion.
Positioning
Adagio Medical positions itself as an innovator in mapping and ablation technology, focusing on precision and real-time feedback to improve outcomes in electrophysiology procedures.
Total Addressable Market (TAM)
The global electrophysiology market is estimated to be in the billions of dollars, and Adagio Medical is positioned to capture a portion of this TAM with its specialized mapping and ablation products.
Upturn SWOT Analysis
Strengths
- Innovative mapping and navigation technology
- Focus on precision and real-time feedback
- Potential for improved outcomes in electrophysiology procedures
Weaknesses
- Limited market share compared to larger competitors
- Reliance on specific product lines
- Funding and capital constraints for R&D and expansion
Opportunities
- Expanding the product portfolio to address a wider range of cardiac arrhythmias
- Partnering with hospitals and clinics to promote product adoption
- International expansion into emerging markets
Threats
- Competition from established medical device companies
- Regulatory hurdles and approval processes
- Technological advancements rendering existing products obsolete
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Adagio Medical faces competition from established medical device companies with larger market shares and broader product portfolios. Adagio Medical's competitive advantage lies in its innovative mapping and ablation technologies and focus on precision and real-time feedback.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not transparently available from public data.
Future Projections: N/A
Recent Initiatives: Adagio Medical continues to innovate in mapping and ablation technologies, focusing on improving the accuracy and efficacy of electrophysiology procedures.
Summary
Adagio Medical shows promise through its innovative mapping and ablation technologies, holding potential to improve cardiac arrhythmia treatment. However, it faces intense competition from giants and needs to build market share and secure funding. The regulatory landscape presents ongoing challenges, but strategic partnerships and international expansion could fuel future growth. Their financial transparency needs improvement for a robust evaluation.
Similar Companies
- JNJ
- ABT
- BSX
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catheter Precision Inc.
Exchange NYSE MKT | Headquaters Fort Mill, SC, United States | ||
IPO Launch date 2018-09-27 | CEO & Executive Chairman Mr. David A. Jenkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 14 | |
Full time employees 14 | |||
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company sells it products through distribution partners, independent sales agents, and direct employees. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.